Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present at the Bank of America Merrill Lynch 2018 Health Care Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on May 17, 2018, at 10:40 a.m. P.T./ 1:40 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic, BMS-986249, a CTLA-4-targeting Probody therapeutic, CX-188, a PD-1-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Christopher Keenan
VP, Investor Relations and Corporate Communications
[email protected]
650-383-0823
